 The bi-specific antibodies with T-cell engager are a novel family of antibodies. And actually it's a very smart way of bringing the lymphocytes into the tumor cell, into the maloma cell. When you look into the CAR T-cells, actually you are educating and training and engineering the lymphocyte in the lab and then you are infusing it. Here it's totally different because actually the whole process is happening in the body, we call it in vivo, in contrast to in vitro. And actually the idea is to have an antibody which is a sort of a targeted bullet, but this antibody is also allowing to bring the T-cell to the maloma cells. This is why we call them bi-specific because actually it's targeting two things. And T-cell engager because it's allowing to engage the T-cell in the fight against multiple maloma. So this is very exciting because actually the products are available off the shelves. They are like any drug like any monoclonal antibody, you can use them whenever you want compared for example to CAR T-cells where you have to wait for some time to engineer the T-cells and so on. So it's a really novel family of antibodies and drugs against multiple maloma which is already showing extremely promising results. So during this ASH 2019 meeting we had a seminal presentation about 30 patients who received a sort of a bi-specific antibody with T-cell engager directed against an antigen called BCMA, B-cell maturation antigen. This is a specific antigen of the maloma cell and in these 30 patients the responses are extremely high although these were patients who were heavily pretreated. They have received an average of five lines of treatment and they have failed these treatments. So they were like in a desperate situation and these B-specific, this B-specific drug it has no name yet, it has a code CC number 69 actually is proving to be highly effective and most importantly the safety was good. And the investigators who presented this work didn't see very severe toxicities especially the one you would expect with this family of drug. So this is very exciting because this novel family of drug is going actually to challenge the need maybe for CAR T-cells in many patients because they are readily available and can be used and highly effective.